Codagenix Incis A Clinical Stage Biotechnology Company Based In Farmingdalenew Yorkwith Operations In Cambridgemassachusettsfounded In 2011The Company Focuses On Synthetic Biology Solutions For Infectious Diseasescancerand Animal Healthit Utilizes A Proprietary Platform That Combines Codon Deoptimization With Live Attenuated Virus Design To Create Stable Viral Genomesbased On Research From Dreckard Wimmer At Stony Brook University The Company S Technology Supports Vaccine Developmentincluding Live Attenuated Vaccines For Respiratory Syncytial Virusrsv Universal Influenzaand Denguecodagenix Is Advancing Several Candidatessuch As Codavax Denva Tetravalent Dengue Vaccine In Preclinical Developmentand Pediatric Rsv And Universal Influenza Vaccines In Clinical Trialsthe Company Also Explores Engineered Viruses For Cancer Therapeutics And Has Programs Targeting Veterinary Pathogenscodagenix Collaborates With Various Investors And Government Agenciesincluding The U Sdepartment Of Defenseto Support Its Research And Development Efforts
